Use: Labeled indications
- Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in…
- Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis…
- Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis
- Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides
- Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or…
- Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis…
- Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy)
- Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by…
Full indications and usage US FDA label
INDICATIONS AND USAGE: Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows:
- Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer
- Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis
- Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis
- Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides
- Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice)
- Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers
- Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy)
- Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis
- Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia
- Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood
- Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus
- Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement
- Diagnostic testing of adrenocortical hyperfunction
- Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. By Intra-articular or Soft Tissue Injection As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Synovitis of osteoarthritis Rheumatoid arthritis Acute and subacute bursitis Acute gouty arthritis Epicondylitis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis By Intralesional Injection Keloids Localized hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare and lichen simplex chronicus (neurodermatitis) Discoid lupus erythematosus Necrobiosis lipoidica diabeticorum Alopecia areata May also be useful in cystic tumors of an aponeurosis or tendon (ganglia)
By Intra-articular or Soft Tissue Injection As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Synovitis of osteoarthritis Rheumatoid arthritis Acute and subacute bursitis Acute gouty arthritis Epicondylitis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis
By Intralesional Injection Keloids Localized hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare and lichen simplex chronicus (neurodermatitis) Discoid lupus erythematosus Necrobiosis lipoidica diabeticorum Alopecia areata May also be useful in cystic tumors of an aponeurosis or tendon (ganglia)
Contraindications
CONTRAINDICATIONS: Systemic fungal infections (see WARNINGS regarding amphotericin B). Hypersensitivity to any component of this product, including sulfites (see WARNINGS).
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION: Dexamethasone sodium phosphate injection, 4 mg per mL– For intravenous, intramuscular, intra-articular, intralesional, and soft tissue injection. Dexamethasone sodium phosphate injection can be given directly from the vial, or it can be added to Sodium Chloride Injection or Dextrose Injection and administered by intravenous drip.
Solutions used for intravenous administration or further dilution of this product should be preservative free when used in the neonate, especially the premature infant. When it is mixed with an infusion solution, sterile precautions should be observed. Since infusion solutions generally do not contain preservatives, mixtures should be used within 24 hours.
DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE AND THE RESPONSE OF THE PATIENT. Intravenous and Intramuscular Injection: The initial dosage of dexamethasone sodium phosphate injection varies from 0.5 to 9 mg a day depending on the disease being treated. In less severe diseases doses lower than 0.5 mg may suffice, while in severe diseases doses higher than 9 mg may be required.
The initial dosage should be maintained or adjusted until the patient’s response is satisfactory. If a satisfactory clinical response does not occur after a reasonable period of time, discontinue dexamethasone sodium phosphate injection and transfer the patient to other therapy. After a favorable initial response, the proper maintenance dosage should be determined by decreasing the initial dosage in small amounts to the lowest dosage that maintains an adequate clinical response.
Patients should be observed closely for signs that might require dosage adjustment, including changes in clinical status resulting from remissions or exacerbations of the disease, individual drug responsiveness, and the effect of stress (e.g., surgery, infection, trauma). During stress it may be necessary to increase dosage temporarily.
If the drug is to be stopped after more than a few days of treatment, it usually should be withdrawn gradually. When the intravenous route of administration is used, dosage usually should be the same as the oral dosage. In certain overwhelming, acute, life-threatening situations, however, administration in dosages exceeding the usual dosages may be justified and may be in multiples of the oral dosages.
The slower rate of absorption by intramuscular administration should be recognized. Shock There is a tendency in current medical practice to use high (pharmacologic) doses of corticosteroids for the treatment of unresponsive shock. The following dosages of dexamethasone sodium phosphate injection have been suggested by various authors: Author Dosage Cavanagh 1 3 mg/kg of body weight per 24 hours by constant intravenous infusion after an initial intravenous injection of 20 mg Dietzman 2 2 to 6 mg/kg of body weight as a single intravenous injection Frank 3 40 mg initially followed by repeat intravenous injection every 4 to 6 hours while shock persists Oaks 4 40 mg initially followed by repeat intravenous injection every 2 to 6 hours while shock persists Schumer 5 1 mg/kg of body weight as a single intravenous injection Administration of high dose corticosteroid therapy should be continued only until the patient’s condition has stabilized and usually not longer than 48 to 72 hours.
Although adverse reactions associated with high dose, short term corticosteroid therapy are uncommon, peptic ulceration may occur. Cerebral Edema Dexamethasone sodium phosphate injection is generally administered initially in a dosage of 10 mg intravenously followed by four mg every six hours intramuscularly until the symptoms of cerebral edema subside.
Response is usually noted within 12 to 24 hours and dosage may be reduced after two to four days and gradually discontinued over a period of five to seven days. For palliative management of patients with recurrent or inoperable brain tumors, maintenance therapy with two mg two or three times a day may be effective. Acute Allergic Disorders In acute, self-limited allergic disorders or acute exacerbations of chronic allergic disorders, the following dosage schedule combining parenteral and oral therapy is suggested: Dexamethasone sodium phosphate injection, 4 mg per mL: first day, 1 or 2 mL (4 or 8 mg), intramuscularly.
Dexamethasone tablets, 0.75 mg: second and third days, 4 tablets in two divided doses each day; fourth day, 2 tablets in two divided doses; fifth and sixth days, 1 tablet each day; seventh day, no treatment; eighth day, follow-up visit. This schedule is designed to ensure adequate therapy during acute episodes, while minimizing the risk of overdosage in chronic cases.
Intra-articular, Intralesional and Soft Tissue Injection Intra-articular, intralesional, and soft tissue injections are generally employed when the affected joints or areas are limited to one or two sites. Dosage and frequency of injection varies depending on the condition and the site of injection. The usual dose is from 0.2 to 6 mg.
The frequency usually ranges from once every three to five days to once every two to three weeks. Frequent intra-articular injection may result in damage to joint tissues. Some of the usual single doses are: Site of Injection Amount of Dexamethasone Phosphate (mg) Large Joints (e.g., Knee) 2 to 4 Small Joints (e.g., Interphalangeal, Temporomandibular) 0.8 to 1 Bursae 2 to 3 Tendon Sheaths 0.4 to 1 Soft Tissue Infiltration 2 to 6 Ganglia 1 to 2 Dexamethasone sodium phosphate injection is particularly recommended for use in conjunction with one of the less soluble, longer-acting steroids for intra-articular and soft tissue injection.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever the solution and container permit.
Intra-articular, Intralesional and Soft Tissue Injection Intra-articular, intralesional, and soft tissue injections are generally employed when the affected joints or areas are limited to one or two sites. Dosage and frequency of injection varies depending on the condition and the site of injection. The usual dose is from 0.2 to 6 mg.
The frequency usually ranges from once every three to five days to once every two to three weeks. Frequent intra-articular injection may result in damage to joint tissues. Some of the usual single doses are: Site of Injection Amount of Dexamethasone Phosphate (mg) Large Joints (e.g., Knee) 2 to 4 Small Joints (e.g., Interphalangeal, Temporomandibular) 0.8 to 1 Bursae 2 to 3 Tendon Sheaths 0.4 to 1 Soft Tissue Infiltration 2 to 6 Ganglia 1 to 2 Dexamethasone sodium phosphate injection is particularly recommended for use in conjunction with one of the less soluble, longer-acting steroids for intra-articular and soft tissue injection.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever the solution and container permit.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosage forms
Philippines
- ) solution for injection: 4 mg/mL (8 mg/2 mL
- Tablet: 3 mg, 4 mg, 500 mcg, 750 mcg
- Solution for injection: 2 mg/mL, 4 mg/mL, 5 mg/5 mL, 5 mg/mL
- Sterile ophthalmic solution: 1 mg/mL
- Ophthalmic solution: 1 mg/mL
- )solution for injection: 4 mg/mL (8 mg/2 mL
Registered products in the Philippines
70 products registered with the Food and Drug Administration (FDA) Philippines list Dexamethasone as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products70
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AdrecortDexamethasone Phosphate (as Sodium) | 4 mg/mL Solution for Injection (I.M./I.V.)Type I Clear Glass Ampoule x 2 mL | Rx | Tai Yu Chemical & Pharmaceutical Co., Ltd.Taiwan | Endure Medical Inc. | DR-XY34096 | Jan 4, 2028 | |
AedexDexamethasone phosphate (as sodium) | 4 mg/mL (8 mg/2 mL) Solution for Injection (I.M./I.V.)Type I clear glass ampoule x 2 mL (Box of 10's) | Rx | Makcur Laboratories LimitedIndia | Dynasty PharmaceuticalsImporter: Hillcross Prime, Inc. | DRP-9806-04 | Jun 9, 2031 | |
AldronDexamethasone (as sodium phosphate) | 5 mg/mL Solution for Injection (IM/IV)USP Type I amber glass ampoule x 1 mL (Box of 10's) | Rx | Friends Pharma (PVT.) LTD.Pakistan | Raquel-Abbas Pharmaceutical & General Merchandise | DRP-17817 | Mar 12, 2031 | |
AlgezoneDexamethasone | 500 mcg TabletAlu-Clear PVC Blister Pack x 20's (Box of 100's) | Rx | San Marino Laboratories CorporationPhilippines | Trader: IAE Pharmaceuticals Corporation | DR-XY19921 | Feb 27, 2027 | |
Cordex 5Dexamethasone Sodium Phosphate | 5 mg/ 5 mL Solution For Injection (IM/IV)1mL USP Type I Clear Borosilicate Glass Ampoule (Box of 10's and 50's) | Rx | Jeil Pharmaceutical Co., Ltd.Korea | Prosel Pharmaceuticals & Distributor's Inc.Importer: Medbridge Inc. | DR-XY45713 | Jan 4, 2027 | |
CortixDexamethasone Phosphate (as Sodium) | 4mg/mL (8mg/2 mL) Solution for Injection (IM/IV)Clear Glass Vial x 2 mL (Box of 1's) | Rx | Kwality Pharmaceuticals Ltd.India | Janamed Corporation | DR-XY40781 | Mar 26, 2032 | |
CortixDexamethasone Phosphate (as Sodium) | 5 mg/mL Solution for Injection (I.M./I.V.) | Rx | Kwality Pharmaceuticals Ltd. | Importer: Clinbaxy International, Inc. | DR-XY40380 | Dec 7, 2026 | |
DecanDexamethasone Sodium Phosphate | 2 mg/mL Solution for Injection (IM/IV)Ampoule x 2 mL (Box of 10 Ampoules) | Rx | Yung Shin Pharm. Ind. Co., Ltd- Taichung Youth FactoryR.O.C | Yung Shin (Philippines), Inc. | DR-XY29210 | Dec 3, 2028 | |
DeciloneDexamethasone | 500 mcg TabletAluminum Blister Pack x 20's (Box of 100's) | Rx | Asian Antibiotics, Inc.Philippines | Trader: UNILAB, Inc. | DR-6271 | Mar 21, 2031 | |
Decilone ForteDexamethasone | 4 mg TabletBlister Pack x 20's (Box of 100's) | Rx | Asian Antibiotics, Inc.Philippines | Trader: UNILAB, Inc. | DR-6518 | May 26, 2031 | |
DexacomDexamethasone Phosphate (as sodium) | 4 mg/mL (8 mg/2 mL) Solution for Injection (I.M./I.V.)Type I clear glass ampoule x 2 mL (Box of 10's) | Rx | Makcur Laboratories LimitedIndia | Compharm, Inc.Importer: Hillcross Prime, Inc. | DRP-9806-05 | Jun 9, 2031 | |
DexacortDexamethasone | 500 mcg TabletAlu/PVC Blister Pack x 20's Box of 100's | Rx | Lloyd Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Euro-Health Care Exponents, Inc. | DRP-448-01 | Apr 19, 2027 | |
DexagoDexamethasone Phosphate (As Sodium) | 4 mg/mL (8 mg/2 mL) Solution for Injection (I.V./I/M.)USP Type I Clear Glass ampoule in a Plastic Tray x 2 mL (Box of 10's) | Rx | Makcur Laboratories LimitedIndia | Afree Pharmaceutical Distribution Corp. | DRP-14696 | Jan 10, 2029 | |
DexahabDexamethasone Phosphate (as sodium) | 5mg/mL Solution For Injection (I.M./I.V.)Type I Glass Ampoule x 1 mL (Box of 50's) | Rx | Union Korea Pharm Co., Ltd.Korea | H&B Pharma International, Inc. | DRP-12147 | Jun 22, 2027 | |
DexamakDexamethasone phosphate (as sodium) | 4 mg/mL (8 mg/2 mL) Solution for Injection (I.M./I.V.)Type I clear glass ampoule x 2 mL (Box of 10's) | Rx | Makcur Laboratories LimitedIndia | Hillcross Prime, Inc. | DRP-9806 | Jun 9, 2031 | |
DexamaxDexamethasone (as sodium Phosphate) | 4 mg/mL Solution for Injection (I.M./I.V.)Amber Glass Ampoule x 2 mL (Box of 10's) | Rx | Shandong Shenglu Pharmaceutical Co., Ltd.China | Importer: AGlobal Care, Inc. | DRP-8114 | Oct 9, 2027 | |
DexametDexamethasone Phosphate (as sodium) | 5 mg/mL Solution for Injection (I.M./I.V.)Type I Glass Ampoule x 1 mL (Box of 10's) | Rx | Union Korea Pharm Co., Ltd.Republic of Korea | Pharmasia-Cuvest IncorporatedImporter: H & B Pharma International Inc. | DRP-12147-01 | Jun 22, 2027 | |
DexamzeDexamethasone phosphate (as sodium) | 4 mg/mL (8 mg/2 mL)Solution for Injection (I.V./I.M.)USP Type I Clear Glass ampoule in a Plastic Tray x 2 mL (Box of 10's) | Rx | Makcur Laboratories LimitedIndia | Onicare Pharma Trading & General MerchandiseImporter: Afree Pharmaceutical Distribution Corp. | DRP-14696-04 | Jan 10, 2029 | |
DexaramDexamethasone Phosphate (as Sodium) | 4 mg/mL (8 mg/2 mL) Solution for Injection (IV/IM)USP Type I clear colorless glass ampoule x 2 mL (Box of 10’s) | Rx | Makcur Laboratories LimitedIndia | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Diafarm Inc. | DRP-12212-01 | Jun 30, 2027 | |
DexarichDexamethasone Phosphate (as Sodium) | 4 mg/mL (8 mg/2 mL) Solution for Injection (IV/IM)USP Type I Clear Colorless Glass ampoule x 2 mL (Box of 10’s) | Rx | Makcur Laboratories LimitedIndia | Ambitech Biopharmaceuticals Inc.Importer: Diafarm Inc. | DRP-12212-02 | Jun 30, 2027 | |
DexasanDexamethasone phosphate (as sodium) | 4 mg/ mL (8 mg/ 2 mL) Solution for Injection (I.M./I.V.)Type I Clear Glass Ampoule x 2 mL (Box of 10's) | Rx | Makcur Laboratories LimitedIndia | Sanimed Pharmaceuticals Inc.Importer: Hillcross Prime, Inc. | DRP-9806-01 | Jun 9, 2031 | |
Dexasaph-Inj 4Dexamethasone | 4 mg/mL (8 mg/2 mL) Solution For Injection (IM/IV)Type I Clear Glass Vial x 2 mL (Box of l's) | Rx | Kilitch Drugs (India) Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-11222 | Feb 15, 2027 | |
DexasoneDexamethasone Sodium Phosphate | 1 mg/mL (0.1% w/v) Ophthalmic Solution (Eye Drops)Polypropylene Plastic Bottle x 5 mL (Box of 1's) | Rx | The IBN SINA Pharmaceutical Industry Ltd.Bangladesh | Endure Medical, Inc. | DR-XY45489 | Jul 5, 2031 | |
DexatDexamethasone | 500 mcg TabletBlister Pack x 20's Box of 100's | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Westfield Pharmaceuticals, Inc. | DRP-2651 | Aug 28, 2028 | |
DexatexDexamethasone Phosphate (as Sodium) | 4 mg/mL (8 mg/2 mL) Solution for Injection (IV/IM)USP Type I clear colorless glass ampoule x 2 mL (Box of 10's) | Rx | Makcur Laboratories Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Diafarm Inc. | DRP-12212-03 | Jun 30, 2027 | |
DexatrinDexamethasone | 500 mcg TabletAlu/PVC Blister Pack x 20's (Box of 100's) | Rx | LLOYD LABORATORIES, INC.Philippines | Trader: FORAMEN PRODUCTS CORPORATION | DR-XY24801 | Feb 11, 2029 | |
DexazelDexamethasone phosphate (as sodium) | 4 mg/mL (8 mg/2 mL) Solution for Injection (I.V./I.M.)USP Type I Clear Glass ampoule in a Plastic Tray x 2mL (Box of 10's) | Rx | Makcur Laboratories LimitedIndia | Pharmazel, Inc.Importer: Afree Pharmaceutical Distribution Corp. | DRP-14696-03 | Jan 10, 2029 | |
DexazenDexamethasone Phosphate (as Sodium) | 4 mg/mL (8 mg/ 2 mL) Solution For Injection (I.M./I.V.)USP Type I amber glass ampoule x 2 mL in plastic tray (Box of 10’s) | Rx | Acies Pharmaceutical Pvt. Ltd.India | Zienac Pharmaceutical Trading | DR-XY49822 | Oct 12, 2028 | |
DexgenDexamethasone (as Sodium Phosphate) | 4 mg/ mL (8 mg/ 2 mL) Solution for Injection (IM/IV)USP Type II Glass Ampoule x 2 mL (Box of 10's) | Rx | Farbe Firma Pvt. Ltd.India | Genzen Pharmaceutical TradingImporter: PhilRx Pharma Inc. | DRP-2312-01 | Jul 9, 2027 | |
DEXGENDexamethasone (as Sodium Phosphate) | 4 mg/mL (8 mg/2 mL) Solution for Injection (IM/IV)USP Type I Borosilicate Glass Ampoule in PVC Tray (Box of 10’s) | Rx | Guizhou Tiandi Pharmaceutical Co., Ltd.China | GENZEN PHARMACEUTICAL TRADINGImporter: AMB HK Enterprises Inc. | DRP-17042-01 | Sep 11, 2030 | |
DexGetDexamethasone phosphate (as sodium) | 4 mg/mL (8 mg/2 mL) Solution for Injection (IM/IV)USP Type I amber glass ampoule x 2 mL (Box of 10's) | Rx | Swiss Parenterals Ltd. (Block-B)India | 2MG Incorporated | DRP-17393 | Dec 10, 2030 | |
DexicortDexamethasone | 500 mcg TabletBlister Pack x 10's Box of 100's | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Basic Pharmaceutical Corp. | DR-XY17988 | Aug 9, 2027 | |
DexmerDexamethasone (as Sodium Phosphate) | 4 mg/mL (8 mg/2 mL) Solution for Injection (IM/IV)USP Type I Borosilicate Glass (Box of 10's) | Rx | Guizhou Tiandi Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-17042 | Sep 11, 2030 | |
DexollenDexamethasone (as sodium phosphate) | 4 mg/mL (8 mg/2 mL) Solution for Injection (IM/IV)Type I Flint Amber Glass Ampoule x 2 mL (Box of 10's) | Rx | Kilitch Drugs (India) Ltd.India | Ollen Pharma Trading, Inc. | DRP-11602 | Mar 31, 2027 | |
DexotabDexamethasone | 500 mcg TabletAlu/PVC Blister Pack x 20's (Box of 100's) | Rx | Drugmaker's Laboratories, Inc.Philippines | Phil Pharmawealth, Inc. | DRP-5260-03 | Aug 19, 2027 | |
Dextar-SDexamethasone phosphate (as sodium) | 4 mg/mL (8 mg/2 mL) Solution for Injection (I.M./I.V.)Type I clear glass ampoule x 2 mL (Box of 10's) | Rx | Makcur Laboratories LimitedIndia | Starpharm, Inc.Importer: Hillcross Prime, Inc. | DRP-9806-02 | Jun 9, 2031 | |
DexticortDexamethasone (as Sodium Phosphate) | 4 mg/mL (8 mg/2mL) Solution for Injection (IM/IV)USP Type II Amber Glass Ampoule x 1 mL and 2 mL in Blister Tray x 10’s (Box of 10’s) | Rx | Zhejiang Ruixin Pharmaceutical Co., Ltd.China | Phil. Pharmawealth, Inc.Importer: Global Pharmatrade | DRP-16243-01 | Jan 2, 2032 | |
DexticortDexamethasone Phosphate (as sodium) | 4 mg/mL Solution for Injection (IM/IV)Clear Type I glass ampoule x 2 mL (Box of 50's) | Rx | LBS Laboratory Limited PartnershipThailand | Phil Pharmawealth, Inc. | DR-XY28147 | Dec 10, 2027 | |
DexticortDexamethasone Sodium Phosphate (equivalent to Dexamethasone Phosphate) | 5 mg/mL Solution for Injection (I.M./I.V.)Clear and Colorless Glass Ampoule x 1 mL (Box of 50's) | Rx | L.B.S. Laboratory Ltd. Part,Thailand | Phil Pharmawealth, Inc. | DR-XY27756 | Aug 13, 2027 | |
DextonDexamethasone Phosphate (as sodium) | 4 mg/mL (8 mg/2 mL) Solution for Injection (IM/IV)USP Type I clear and colorless glass vial x 2 mL (Box of 1's) | Rx | T.P. Drug Laboratories (1969) Co., Ltd.Thailand | Lordla Pharma Sales | DRP-701 | May 25, 2037 | |
DextonDexamethasone Sodium Phosphate | 5 mg/mL Solution for Injection (I.M./ I.V.)USP Type I Clear and Colorless Glass Ampoule x 1 mL (Box of 50’s) | Rx | T.P. Drug Laboratories (1969) Co., Ltd.Thailand | LORDLA PHARMA SALES | DR-XY24222 | May 28, 2028 | |
DextracentDexamethasone phosphate (as sodium) | 4 mg/mL (8 mg/2 mL) Solution for Injection (I.V./I.M.)USP Type I Clear Glass ampoule in a Plastic Tray x 2 mL (Box of 10's) | Rx | Makcur Laboratories LimitedIndia | Central West Medicale Inc.Importer: Afree Pharmaceutical Distribution Corp. | DRP-14696-05 | Jan 10, 2029 | |
DrenexDexamethasone | 3 mg TabletFoil Strip Pack x 10's Box of 50's | Rx | Asian Antibiotics, Inc.Philippines | Trader: United American Pharmaceuticals, Inc. | DR-7198 | Jul 9, 2027 | |
DrenexDexamethasone | 750 mcg TabletAluminum Flexible Foil x 10's Box of 50's | Rx | Asian Antibiotics, Inc.Philippines | Trader: United American Pharmaceuticals, Inc. | DR-6722 | May 3, 2027 | |
DrezipexDexamethasone Phosphate (as Sodium) | 4 mg/mL (8 mg/2 mL) Solution for Injection (IV/IM)USP Type I clear colorless glass ampoule x 2 mL (Box of 10's) | Rx | Makcur Laboratories Ltd.India | Diafarm, Inc. | DRP-12212 | Jun 30, 2027 | |
EodexDexamethasone phosphate (as sodium) | 4 mg/mL (8 mg/2mL) Solution for Injection (I.V./I.M.)USP Type I Amber Glass Vial with Grey Rubber Stopper and Aluminum Seal with Green Flip-off Cap x 2 mL (Box of 1's) | Rx | Zee Laboratories LimitedIndia | Eon Pharmatek Inc. | DR-XY47563 | Nov 23, 2026 | |
EzydoxDexamethasone Sodium Phosphate | 1mg/mL (0.1% w/v) Sterile Ophthalmic Solution15 mL White LDPE Plastic Bottle, Color Cap Eye Dropper, and White color plug (Box of 1's) | Rx | Skymap Healthcare Pvt. Ltd.India | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-14326 | Aug 24, 2028 | |
HamdexDexamethasone (as sodium phosphate) | 4 mg/mL (8 mg/2 mL) Solution for Injection (IM/IV)USP type II glass ampoule x 2 mL (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-17255 | Oct 24, 2030 | |
ImpodexDexamethasone | 500 mcg TabletAlu/PVC Blister pack x 20's Box of 100's | Rx | Drugmaker's Laboratories, Inc.Philippines | — | DRP-5260 | Aug 19, 2027 | |
MetacortDexamethasone (as Sodium Phosphate) | 4 mg/mL (8 mg/2 mL) Solution for Injection (IM/IV) | Rx | Zhejiang Ruixin Pharmaceuticals Co., Ltd. | Global Pharmatrade | DR-XY40472 | Jan 2, 2027 | |
MetacortDexamethasone (as Sodium Phosphate) | 4 mg/mL (8 mg/2mL) Solution for Injection (IM/IV)USP Type II Amber Glass Ampoule x 1 mL and 2 mL in Blister Tray x 10’s (Box of 10’s) | Rx | Zhejiang Ruixin Pharmaceutical Co., Ltd.China | Global Pharmatrade | DRP-16243 | Jan 2, 2032 | |
MethacoreDexamethasone (as sodium phosphate) | 4mg/mL (8mg/2mL) Solution for Injection (IM/IV)Type I Amber Glass Ampoule x 2mL (Box of 10's) | Rx | Scott-Edil Pharmacia LimitedIndia | Greencore Pharma Inc.Trader: N/A | DRP-17792 | Mar 11, 2031 | |
MohsidexDexamethasone (as Sodium Phosphate) | 4 mg/mL (8 mg/2 mL) Solution for Injection (IM/ IV)USP Type II Glass Ampoule x 2 mL (Box of 10's) | Rx | Farbe FirmaIndia | Importer: PhilRx Pharma Inc. | DRP-2312 | Jul 9, 2027 | |
NidexDexamethasone (as sodium phosphate) | 1mg/mL (0.1% w/v) Ophthalmic Solution (Drops)10mL in 15mL LDPE White Opaque Bottle (Box of 1's) | Rx | Nitin Lifesciences Ltd.India | Seapharma International, Inc. | DRP-7146 | Oct 10, 2029 | |
NoneDexamethasone phosphate (as sodium) | 1 mg/ mL (0.1 % w/v) Sterile Ophthalmic Solution (Eye Drops)5 mL LDPE Dropper Bottle with HDPE Tamper-proof Cap (Box of 1's) | Rx | Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt | Ambica International Corporation | DRP-9131 | Sep 15, 2030 | |
NoneDexamethasone phosphate (as sodium) | 4 mg / mL (8 mg/2 mL) Solution for Injection (I.V./I.M.)USP Type I Clear Glass ampoule in a Plastic Tray x 2 mL (Box of 10's) | Rx | Makcur Laboratories LimitedIndia | Bliss Pharma Distribution and Consultancy Corp.Importer: Afree Pharmaceutical Distribution Corp. | DRP-14696-01 | Jan 10, 2029 | |
NoneDexamethasone phosphate (as sodium) | 4 mg/mL (8 mg/2 mL) Solution for Injection (I.V./I.M.)USP Type I Clear Glass ampoule in a Plastic Tray x 2 mL (Box of 10's) | Rx | Makcur Laboratories LimitedIndia | Genace Pharma DistributorImporter: Afree Pharmaceutical Distribution Corp. | DRP-14696-02 | Jan 10, 2029 | |
NoneDexamethasone | 500mcg TabletAlu/PVC Blister Pack x 20's (Box of 100's) | Rx | Drugmaker's Laboratories, Inc.Philippines | TGP Pharma Inc. | DRP-5260-01 | Aug 19, 2027 | |
NovaxamethDexamethasone phosphate (as sodium) | 1 mg/mL (0.1% w/v) Sterile Ophthalmic Solution (Eye Drops)Low Density Polyethylene (LDPE) Container with White Low Density Polyethylene (LDPE) Screw Cap x 5 mL (Box of 1's) | Rx | Ahlcon Parenterals (India) LimitedIndia | Medinova Pharmaceutical Inc. | DRP-10955 | Dec 29, 2026 | |
OcubidexDexamethasone phosphate (as sodium) | 1 mg/mL (0.1% w/v) Sterile Ophthalmic Solution (Eye Drops)Low Density Polyethylene (LDPE) Plastic Droptainer with Low Density Polyethylene (LDPE) Screw Cap × 5 mL (Box of 1's) | Rx | Ahlcon Parenterals (India) LimitedIndia | Ambicare Pharmaceuticals Inc.Trader: Highkon Pharma | DRP-10957 | Dec 23, 2031 | |
OQ-DEXDexamethasone phosphate (as sodium) | 1 mg/ mL (0.1 % w/v) Sterile Ophthalmic Solution (Eye Drops)5 mL LDPE Dropper Bottle with HDPE Tamper-proof Cap (Box of 1’s) | Rx | Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt | Visionaire Pharmaceutical Products TradingImporter: Ambica International Corporation | DRP-9131-02 | Sep 15, 2030 | |
OzurdexDexamethasone | 700 mcg Sustained Release Sterile Rod-Shaped Implant for Ophthalmic Intravitreal InjectionOne (1) Implant with Single-use Plastic Applicator System in White Laminated Aluminum Foil Pouch (Box of 1's) | Rx | Allergan Pharmaceuticals IrelandIreland | ZUELLIG PHARMA CORPORATION | DR-XY43123 | Jan 8, 2029 | |
PenatoneDexamethasone phosphate (as sodium) | 4mg/mL Solution for Injection (I.V./I.M.)Type I Amber Colored Glass Ampoule x 2 mL (Box of 10's) | Rx | Duopharma (M) Sdn. Bhd.Malaysia | Importer: DB (Philippines), Inc. | DR-XY48850 | Aug 17, 2028 | |
PhenodexDexamethasone phosphate (as sodium) | 4 mg/mL (8 mg/2 mL) Solution for Injection (I.M./I.V.)Type I clear colorless glass vial x 2 mL (net content) (Box of 1's and 10's) | Rx | Vesco Pharmaceutical Company LimitedThailand | Euro-Care Products Philippines | DRP-10357 | Sep 15, 2031 | |
SaphsodexDexamethasone | 4 mg TabletAlu/PVC Blister Pack of 10’s and 20’s (Box of 100’s) | Rx | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-18552 | Jul 30, 2031 | |
ScancortinDexamethasone Phosphate (as Sodium) | 5 mg/mL Solution for Injection (IV/IM)Type I Borosilicate Colorless Glass Ampoule in 1 mL (net content) (Box of 10's and 100's) | Rx | PT. Sanbe Farma (Unit 3)Indonesia | Phoenix Pharmaceutical, Inc. | DR-XY46180 | Nov 28, 2029 | |
SitisoneDexamethasone phosphate (as sodium) | 4mg/mL Solution for Injection (IM/IV)2mL - Capacity Low Borosilicate Glass Ampoule x 1mL (net content) in Plastic Tray (Box of 10's) | Rx | Tianjin KingYork Group Hubei TianYao Pharmaceutical Co., LtdChina | Sahar International Trading Inc.Trader: ZLF Pharmaceutical Limited | DR-XY49461 | Aug 5, 2030 | |
SterasoneDexamethasone | 500 mcg TabletAlu/PVC Blister Pack x 20's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | 999 Seth Pharmaceutical Inc.Trader: Euro-Health Care Exponents, Inc. | DRP-448 | Apr 19, 2027 | |
VexametDexamethasone | 500 mcg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Vamsler Phils. Incorporated | DRP-9924 | Oct 9, 2028 | |
VistadexamDexamethasone phosphate (as sodium) | 1 mg/ mL (0.1 % w/v) Sterile Ophthalmic Solution (Eye Drops)5 mL LDPE Dropper Bottle with HDPE Tamper-proof Cap (Box of 1's) | Rx | Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt | Vista Pharma, Inc.Importer: Ambica International Corporation | DRP-9131-01 | Sep 15, 2030 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS: Because rare instances of anaphylactoid reactions have occurred in patients receiving parenteral corticosteroid therapy, appropriate precautionary measures should be taken prior to administration, especially when the patient has a history of allergy to any drug. Anaphylactoid and hypersensitivity reactions have been reported for dexamethasone sodium phosphate (see ADVERSE REACTIONS).
In patients on corticosteroid therapy subjected to any unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated. Immunosuppression and Increased Risk of Infection Corticosteroids, including dexamethasone sodium phosphate injection, suppress the immune system and increase the risk of infection with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic pathogens.
Corticosteroids can: Reduce resistance to new infections Exacerbate existing infections Increase the risk of disseminated infections Increase the risk of reactivation or exacerbation of latent infections Mask some signs of infection Corticosteroid-associated infections can be mild but can be severe and at times fatal. The rate of infectious complications increases with increasing corticosteroid dosages.
Monitor for the development of infection and consider dexamethasone sodium phosphate injection withdrawal or dosage reduction as needed. Tuberculosis If dexamethasone sodium phosphate injection is used to treat a condition in patients with latent tuberculosis or tuberculin reactivity, tuberculosis may occur. Closely monitor such patients for reactivation.
During prolonged therapy, patients with latent tuberculosis or tuberculin reactivity should receive chemoprophylaxis. Varicella Zoster and Measles Viral Infections Varicella and measles can have a serious or even fatal course in non-immune patients taking corticosteroids, including dexamethasone sodium phosphate injection.
In corticosteroid-treated patients who have not had these diseases or are nonimmune, particular care should be taken to avoid exposure to varicella and measles: If a dexamethasone sodium phosphate injection-treated patient is exposed to varicella, prophylaxis with varicella zoster immune globulin may be indicated. If varicella develops, treatment with antiviral agents may be considered.
If a dexamethasone sodium phosphate injection-treated patient is exposed to measles, prophylaxis with immunoglobulin may be indicated. Hepatitis B Virus Reactivation Hepatitis B virus reactivation can occur in patients who are hepatitis B carriers treated with immunosuppressive dosages of corticosteroids, including dexamethasone sodium phosphate injection.
Reactivation can also occur infrequently in corticosteroid-treated patients who appear to have resolved hepatitis B infection. Screen patients for hepatitis B infection before initiating immunosuppressive (e.g., prolonged) treatment with dexamethasone sodium phosphate injection. For patients who show evidence of hepatitis B infection, recommend consultation with physicians with expertise in managing hepatitis B regarding monitoring and consideration for hepatitis B antiviral therapy.
Fungal Infections Corticosteroids, including dexamethasone sodium phosphate injection, may exacerbate systemic fungal infections; therefore, avoid dexamethasone sodium phosphate injection use in the presence of such infections unless dexamethasone sodium phosphate injection is needed to control drug reactions. For patients on chronic dexamethasone sodium phosphate injection therapy who develop systemic fungal infections, dexamethasone sodium phosphate injection withdrawal or dosage reduction is recommended.
Amebiasis Corticosteroids, including dexamethasone sodium phosphate injection, may activate latent amebiasis. Therefore, it is recommended that latent amebiasis or active amebiasis be ruled out before initiating dexamethasone sodium phosphate injection in patients who have spent time in the tropics or patients with unexplained diarrhea.
Strongyloides Infestation Corticosteroids, including dexamethasone sodium phosphate injection, should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation. In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.
Cerebral Malaria Avoid corticosteroids, including dexamethasone sodium phosphate injection, in patients with cerebral malaria. Kaposi’s Sarcoma Kaposi’s sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement of Kaposi’s sarcoma.
Dexamethasone sodium phosphate injection contains sodium bisulfite, a sulfite that may cause allergic- type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low.
Sulfite sensitivity is seen more frequently in asthmatic than in non- asthmatic people. Corticosteroids may exacerbate systemic fungal infections and therefore, should not be used in the presence of such infections unless they are needed to control drug reactions due to amphotericin B. Moreover, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive failure.
Drug-induced secondary adrenocortical insufficiency may result from too rapid withdrawal of corticosteroids and may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted.
If the patient is receiving steroids already, dosage may have to be increased. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently. Moreover, corticosteroids may affect the nitroblue-tetrazolium test for bacterial infection and produce false negative results.
In cerebral malaria, a double-blind trial has shown that the use of corticosteroids is associated with prolongation of coma and a higher incidence of pneumonia and gastrointestinal bleeding. Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses.
Average and large doses of cortisone or hydrocortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary.
All corticosteroids increase calcium excretion. Administration of live virus vaccines, including smallpox, is contraindicated in individuals receiving immunosuppressive doses of corticosteroids. If inactivated viral or bacterial vaccines are administered to individuals receiving immunosuppressive doses of corticosteroids, the expected serum antibody response may not be obtained.
However, immunization procedures may be undertaken in patients who are receiving corticosteroids as replacement therapy, e.g., for Addison’s disease. Literature reports suggest an apparent association between use of corticosteroids and left ventricular free wall rupture after a recent myocardial infarction; therefore, therapy with corticosteroids should be used with great caution in these patients.
Serious Neurologic Adverse Reactions with Epidural Administration Serious neurologic events, some resulting in death, have been reported with epidural injection of corticosteroids. Specific events reported include, but are not limited to, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, and stroke. These serious neurologic events have been reported with and without use of fluoroscopy.
The safety and effectiveness of epidural administration of corticosteroids has not been established, and corticosteroids are not approved for this use. Pregnancy Teratogenic Effects: Pregnancy Category C– Since adequate human reproduction studies have not been done with corticosteroids, use of these drugs in pregnancy or in women of childbearing potential requires that the anticipated benefits be weighed against the possible hazards to the mother and embryo or fetus.
Infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism. Corticosteroids appear in breast milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other unwanted effects. Mothers taking pharmacologic doses of corticosteroids should be advised not to nurse.
Serious Neurologic Adverse Reactions with Epidural Administration Serious neurologic events, some resulting in death, have been reported with epidural injection of corticosteroids. Specific events reported include, but are not limited to, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, and stroke. These serious neurologic events have been reported with and without use of fluoroscopy. The safety and effectiveness of epidural administration of corticosteroids has not been established, and corticosteroids are not approved for this use.
Pregnancy Teratogenic Effects: Pregnancy Category C– Since adequate human reproduction studies have not been done with corticosteroids, use of these drugs in pregnancy or in women of childbearing potential requires that the anticipated benefits be weighed against the possible hazards to the mother and embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism.
Corticosteroids appear in breast milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other unwanted effects. Mothers taking pharmacologic doses of corticosteroids should be advised not to nurse.
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS: To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Fluid and electrolyte disturbances: Sodium retention Fluid retention Congestive heart failure in susceptible patients Potassium loss Hypokalemic alkalosis Hypertension Musculoskeletal: Muscle weakness Steroid myopathy Loss of muscle mass Osteoporosis Pathologic fracture of long bones Vertebral compression fractures Aseptic necrosis of femoral and humeral heads Tendon rupture Gastrointestinal: Peptic ulcer with possible subsequent perforation and hemorrhage Perforation of the small and large bowel, particularly in patients with inflammatory bowel disease Pancreatitis Abdominal distention Ulcerative esophagitis Dermatologic: Impaired wound healing Thin fragile skin Petechiae and ecchymoses Erythema Increased sweating May suppress reactions to skin tests Burning or tingling, especially in the perineal area (after IV injection) Other cutaneous reactions, such as allergic dermatitis, urticaria, angioneurotic edema Neurologic: Convulsions Increased intracranial pressure with papilledema (pseudotumor cerebri) usually after treatment Vertigo Headache Psychic disturbances Endocrine: Menstrual irregularities Development of cushingoid state Suppression of growth in children Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery, or illness Decreased carbohydrate tolerance Manifestations of latent diabetes mellitus Increased requirements for insulin or oral hypoglycemic agents in diabetics Hirsutism Ophthalmic: Posterior subcapsular cataracts Increased intraocular pressure Glaucoma Exophthalmos Metabolic: Negative nitrogen balance due to protein catabolism Cardiovascular: Myocardial rupture following recent myocardial infarction (see WARNINGS) Other: Anaphylactoid or hypersensitivity reactions Thromboembolism Weight gain Increased appetite Nausea Malaise Hiccups The following additional adverse reactions are related to parenteral corticosteroid therapy: Rare instances of blindness associated with intralesional therapy around the face and head Hyperpigmentation or hypopigmentation Subcutaneous and cutaneous atrophy Sterile abscess Post-injection flare (following intra-articular use) Charcot-like arthropathy
Pharmacokinetics
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY: Dexamethasone sodium phosphate has a rapid onset but short duration of action when compared with less soluble preparations. Because of this, it is suitable for the treatment of acute disorders responsive to adrenocortical steroid therapy. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states.
Their synthetic analogs, including dexamethasone, are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body’s immune responses to diverse stimuli. At equipotent anti-inflammatory doses, dexamethasone almost completely lacks the sodium-retaining property of hydrocortisone and closely related derivatives of hydrocortisone.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Dexamethasone 4 mg Tablet | ₱18.00–₱21.70Reference ₱18.00 | per tablet | DPRI procurement range |
| Dexamethasone 4 mg/mL, 2 mL Ampule | ₱6.48–₱28.50Reference ₱11.21 | per ampule | DPRI procurement range |
| Dexamethasone 4 mg/mL, 2 mL Vial | ₱7.22–₱38.16Reference ₱11.29 | per vial | DPRI procurement range |
| Dexamethasone 5 mg/mL,1 mL Ampule | ₱23.62–₱104.89Reference ₱23.62 | per ampule | DPRI procurement range |
| Dexamethasone 500 mcg Tablet | ₱0.75–₱18.00Reference ₱0.75 | per tablet | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Dexamethasone |
| PNF listing | Oral: 500 micrograms, 750 micrograms, 3 mg and 4 mg tablet |
| PNF listing | Inj.: 4 mg/mL, 1 mL and 2 mL ampul/vial (IM, IV) (as sodium phosphate) |
| PNF listing | Inj.: 5 mg/mL, 1 mL ampul (IM, IV) (as sodium |
| PNF listing | Inj.: phosphate) |
| PNF listing | Eye Drops Suspension: 0.1%, 5 mL bottle |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Dexamethasone Sodium Phosphate · Sportpharm LLC [US FDA-approved label, version 1, August 31, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9822a5c3-d3f1-4e0b-9963-32b22740e10e
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .
